AnaMar AB is developing a first-in-class, anti-fibrotic medicine to prevent, slow and heal scarring caused by fibrosis through its patented suite of serotonin (5-HT2B) receptor antagonists. Our selective, oral 5-HT2B receptor antagonist, AM1476, has broad therapeutic potential across fibrotic conditions, which affect millions of patients but have limited, if any, treatment options, including systemic fibrotic disorders and organ-specific fibrotic disorders such as interstitial lung diseases. AM1476 performed successfully in in vitro and in vivo models of fibrosis, as well as demonstrating favourable safety and pharmacokinetic profiles in Phase I clinical studies. It offers a unique dual-action approach to treat skin and lung manifestations of systemic sclerosis. By targeting peripheral 5-HT2B receptors our antagonists will halt key signaling pathways associated with fibrosis. This specifically reduces 5-HT-induced myofibroblast and macrophage activity and TGF-β production, minimizing side effects and interactions with other medicines. We are combining our innovative therapeutic platform with biomarkers and genetic analysis to identify those patients most likely to benefit from treatment, using our heritage in diagnostics to ensuring the best outcomes for those with fibrosis.